Seagen Inc. (SGEN)
150.09 -0.00 (-0.00%)
After hours: 4:04PM EST
Chart Events
Performance Outlook
| Previous Close | 155.02 |
| Open | 154.21 |
| Bid | 150.34 x 1000 |
| Ask | 150.67 x 1200 |
| Day's Range | 148.37 - 156.31 |
| 52 Week Range | 90.57 - 213.94 |
| Volume | 988,767 |
| Avg. Volume | 1,077,688 |
| Market Cap | 27.191B |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | 44.54 |
| EPS (TTM) | 3.37 |
| Earnings Date | Apr 28, 2021 - May 03, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 195.20 |
Fair Value
Related Research
- Business Wire
Seagen to Present at the Cowen 41st Annual Healthcare Conference
Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 2:40 p.m. Eastern Time. The presentation will be webcast live and available for replay from Seagen’s website at www.seagen.com in the Investors section.
- Business Wire
Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for PADCEV® (enfortumab vedotin-ejfv). One submission, based on the phase 3 EV-301 trial, seeks to convert PADCEV’s accelerated approval to regular approval. The second submission, based on the pivotal trial EV-201’s second cohort, requests an expansion of the current label to include patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor and are ineligible for cisplatin.
- PR Newswire
Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced completion of submissions for two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for PADCEV® (enfortumab vedotin-ejfv). One submission, based on the phase 3 EV-301 trial, seeks to convert PADCEV's accelerated approval to regular approval. The second submission, based on the pivotal trial EV-201's second cohort, requests an expansion of the current label to include patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor and are ineligible for cisplatin.
